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ABSTRACT 
Drug targeting is a kind of phenomenon in which drug gets distributed in the body in such a manner that the drug interacts with the 
target tissue at a cellular or subcellular level to achieve a desired therapeutic response at a desire site without undesirable interactions 
at other sites. This can be achieved by modern methods of targeting the drug delivery system such as niosomes. Niosomes are the 
type of non-ionic surfactant vesicles, which are biodegradable, non-toxic, more stable and inexpensive, a new approach to 
liposomes. Their structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes. 
The niosomes have the tendency to load different type of drugs. This review article represents the structure of niosome, advantages, 
disadvantages, the methods for niosome preparation and characterization of pharmaceutical NSVs. 
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INTRODUCTION  
Drug targeting can be defined as the ability to direct a 
therapeutic agent at the desired site of action with little 
or no interaction with other tissue. Controlled drug 
delivery system is designed to obtain a desirable drug 
release profile for a longer period of time. There are 
various techniques to obtain controlled release system, 
one of them is niosomes. Niosomes are non-ionic 
surfactant vesicles with microscopic lamellar bilayer 
structure formed by self association of hydrated 
surfactant monomers. The multilamellar or unilamellar 
structure of niosomes is formed by mixing non-ionic 
surfactant, cholesterol and diethyl ether along with 
subsequent hydration in aqueous media 
1
. 
Niosomes are microscopic lamellar structures of the size 
range between 10 to1000 nm. The niosome consists of 
non-immunogenic, biodegradable and biocompatible 
surfactants. Niosomes are better than liposomes and its 
higher chemical stability of surfactants than 
phospholipids which are easily hydrolyzed due to the 
ester bond and cost effective
2
. 
The application of vesicular (lipid vesicles and non-
ionic surfactant vesicles) systems in cosmetics and for 
therapeutic response may offer several advantages are-  
1) Higher patient compliance in comparison with oily 
dosage forms.  
2) The vesicles may act as a depot, releasing the drug in 
a controlled manner. 
3) Accommodate drug molecules with a wide range of 
solubilities 
3
. 
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Figure 1: Structure of Niosome 
 
COMPOSITION OF NIOSOMES- (Gayatri et al., 2000) 
Two components use in niosome preparation are 
 Cholesterol 
 Non-ionic surfactants 
A. Cholesterol is a steroid derivative, which is used to 
provide rigidity and proper shape, conformation to 
niosome form. 
B. Non-ionic Surfactants are generally used for the 
preparation of niosomes. 
Examples:  a. Tweens (20, 40, 60, 80) 
                    b. Spans (Span 60, 40, 20, 85, 80) 
                      c. Brijs (Brij 30, 35, 52, 58, 72, 76).
 
DIFFERENT TYPES OF NON-IONIC SURFACTANTS                                             
Table 1: Different Types of Non-Ionic Surfactants 
Type of Non-Ionic Surfactant Examples 
Fatty alcohol                                       Cetyl alcohol, stearyl alcohol, cetostearylalcohol, oleyl alcohol 
Ethers Brij, Decyl glucoside, Lauryl glucoside, Octyl glucoside, Triton X-100, Nonoxynol-9 
Esters Glyceryl laurate, Polysorbates, Spans 
Block copolymers                                Poloxamers 
 
TYPES OF NIOSOMES  
The various types of niosomes are as: 
i) Multi lamellar vesicles (MLV), 
ii) Large unilamellar vesicles (LUV), 
iii) Small unilamellar vesicles (SUV). 
Table 2: Types of Niosomes 
Parameters Multi lamellar Vesicles Small Unilamellar Vesicles Large Unilamellar Vesicles 
Vesicle Size Greater than 0.05μm 0.025 – 0.05μm Greater than 0.10μm 
Method of 
Preparation 
 
Hand Shaking Method 
 
Sonication 
Extrusion Method 
Solvent Dilution Technique 
Reverse Phase evaporation Method 
 
 
ADVANTAGES 
1.  Niosome can accommodate a variety of drug 
moieties such as hydrophilic, lipophilic, as well as 
ampiphilic drugs.  
2. Vesicle characteristics can be controlled by altering 
the composition of vesicle, size lamellarity, surface 
charge, tapped volume and concentration.  
3. The drug can release in the sustained/controlled 
manner.  
4. No special conditions required for handling and 
storage of surfactants. 
5. Due to the depot formulation, it allows controlled 
release of the drug.  
6. Poorly soluble drugs have increased oral 
bioavailability.  
7. Surfactants posses following response 
biodegradable, biocompatible, non-toxic and non-
immunogenic.  
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8. They can protect the active moiety from biological 
circulation. 
9. Drug protection from enzyme metabolism.  
10. Improve the stability of entrapped drug.  
11. They can enhance the permeation of drugs through 
the skin.  
12. They improve the therapeutic profile of the drug 
molecules due to delayed clearance from the 
circulation 
4,5
. 
 
DISADVANTAGES 6 
 
Figure 2: Disadvantages of niosomes
Table 3: Comparison between Niosomes and Liposomes
7
 
LIPOSOMES NIOSOMES 
More Expensive Less Expensive 
Require special methods for storage and handling of the 
final formulation. 
No special methods require for such formulations. 
Phospholipids may be neutral and charged. Non-ionic surfactant is uncharged. 
 
FORMULATION AND EVALUATION OF NIOSOMES 
Method of preparation 
A. Passive Trapping Techniques - This category includes most of the techniques used in preparation of niosomes in 
which drug is incorporated during the preparation of niosomes i.e. during their formation. 
1. Sonication - Mixture of drug solution in the buffer, surfactant and cholesterol 
 
 Sonicated with a titanium probe sonicator at 60°C for 3 minutes to yield niosomes 
8. 
2. Ether Injection Method –  
Niosomes by slowly introduce in a solution of surfactant dissolve in diethyl ether into warm water maintain at 60 C 
 
Mixture in ether is injected through 14-gauge needle into an aqueous solution of material 
 
Vaporization of ether leads to the formation of the single layer vesicles 
 
Diameter of the vesicle range from 50 to 1000 nm depends upon the conditions use 
9,10
. 
3. Reverse Phase Evaporation Technique - Cholesterol and surfactant (ratio of 1:1) dissolves in the mixture of 
organic solvent (ether and chloroform). Addition of the aqueous drug solution to this and water in oil emulsion is 
formed; two phases are sonicated at 4-5ºC. The emulsion is dried in a rotary evaporator at 40°C to form a semisolid gel 
of large vesicles. Small amounts of phosphate buffered saline (PBS) are added to the clear gel and sonicate again. The 
organic phase is removed at 40ºC and lower pressure. Viscous niosomal suspension is further diluted with phosphate 
buffered saline, then heat on a water bath at 60ºC for 10 min to form niosomes 
11.
 
 4.  The “Bubble” Method  
Bubbling unit involves round-bottomed flask with three neck position in water bath to control the temperature 
 
Water-cool reflux is positioned in the first neck and thermometer is positioned in the second neck and nitrogen supply 
through the third neck 
 
Cholesterol and surfactant are dispersed in the buffer (pH 7.4) at 70°C 
Dispersion mixing for 15 seconds with high shear homogenizer 
 
“Bubbled” at 70°C using nitrogen gas 12. 
Aggregation 
Leaking of Entrapped 
Drug 
Physical instability Time consuming 
DISADVANTAGES 
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5. Hand Shaking Method (Thin Film Hydration Technique/Rotary Evaporator) –  
The mixing ingredients - surfactant and cholesterol and charge inducer 
 
Dissolves in a volatile organic solvent (chloroform, diethyl ether or methanol) in a round bottom flask 
 
By using a rotary evaporator organic solvent is evaporated at room temperature 20°C 
 
Forming a thin layer of solid mixture 
 
The dry surfactant film can be re-hydrated with an aqueous phase at 0-60°C with gentle agitation 
 
      Formation of niosomes 
13
. 
6. Multiple Membrane Extrusion Method -Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform 
forms thin film by rotary evaporator. The film hydrates with aqueous drug polycarbonate membranes. Solution and 
resultant suspension extrude through polycarbonate membrane and placed in series for up to 8 passages. It is a good 
method for niosome size control 
14.
 
7. Ethanol Injection Method  
An ethanol solution of surfactant is injected rapidly through a fine needle 
 
Into excess of saline or other aqueous medium 
 
Vaporization of ethanol 
 
Formation of vesicles 
15.
 
8. Micro Fluidization – In this technique the principle involves is submerged jet principle in which two fluidized 
streams interact with each other at ultra high velocities and in the micro channels within the interaction chamber. Thin 
liquid sheet impingements along with common front are arranged such as that the energy supplies remain same within 
the area of niosomes formation, formation of niosomal vesicles of greater uniformity, smaller size and better 
reproducibility 
16.
 
B. Active Trapping Techniques - This includes the loading of the drug after the formation of niosomes. The niosomes 
are prepared and then the drug is load of maintaining a pH gradient or ion gradients to facilitate uptake of drug into 
niosomes. Various advantages of noisome form are 100% entrapment, high drug lipid ratios, absence of leakage, cost 
effectiveness and suitability for labile drugs. 
1. Trans Membrane pH Gradient Drug Uptake Process  
 In remote loading process surfactants and cholesterol are dissolved in organic solvent (chloroform) 
 
Solvent evaporates under reduced pressure to get a thin film on the wall of the round bottom flask 
 
Film hydrates with 300 mM citric acid (pH4.0) by vortex mixing 
 
Multilamellar vesicles are frozen and thawed 3 times and later sonication 
 
For niosomal suspension, aqueous solution containing 10 mg/ml of drug is added and vortex 
 
Sample pH is raises to 7.0-7.2 with 1M disodium phosphate 
 
The mixture is later heated at 60°C for 10 minutes to yield niosomes 
17
. 
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C. Miscellanous Methods – 
1. Emulsion Method: This is a simple method to form 
niosome in which oil in water (o/w) emulsion is 
prepared from an organic solution of surfactant, 
cholesterol, and an aqueous solution of the drug. Finally, 
the organic solvent is evaporated leaving niosomes 
dispersed in the aqueous phase 
18.
 
2. Heating Method: This method is in one-step, 
scalable and non-toxic and also based on the patent 
procedure. A suitable aqueous medium such as buffer 
distilled water, etc. in which mixtures of non-ionic 
surfactants, cholesterol and/or charge inducing 
molecules are added in the presence of the polyol like as 
glycerol. The mixture is heated with (at low shear 
forces) until the vesicles were form 
19
. 
3. Formation of Niosomes from Proniosomes: 
Proniosome is a dry formulation in which each water-
soluble particle are covered with a thin film of dry 
surfactant. The niosomes are recognizing by the adding 
aqueous phase at T > Tm with brief agitation. T is the 
Temperature and Tm is the mean phase transition 
temperature 
20
. 
Carrier + surfactant = proniosomes, 
Proniosomes + water = niosomes. 
4. Lipid Injection Method: This method does not 
require expensive organic phase. Mixture of lipids and 
surfactant is first melted and then injected into a highly 
agitate heated aqueous phase contains the dissolved 
drug. Drug dissolves in molten lipid and the mixture 
will be injected into agitate, heat aqueous phase 
containing surfactant. 
 
FACTORS INFLUENCING NIOSOMAL FORMULATION:
21-25
 
 
Figure 3: Factors Influencing Niosomal Formulation 
 
1. Nature of Surfactant: Increase in the HLB value of 
surfactants leads to the increase in the mean size of 
niosomes due to the decrease in surface free energy with 
an increase in the surfactant hydrophobicity. The 
bilayers of the niosomes can exist either as a liquid state 
or in a gel state. It depends upon the temperature, type of 
surfactant and cholesterol. Alkyl chains are well ordered 
in the gel state, whereas disordered in the liquid state. 
Entrapment efficiency is affected by the gel, liquid phase 
transition temperature (TC) of the surfactant. 
Eg: span 60 with higher TC exhibits better entrapment. 
The HLB value of surfactants ranging between 14 and 
17 are not suitable for niosomal preparations. Decrease 
in the HLB value of surfactants from 8.6 to 1.7 
decreases the entrapment efficiency and highest 
entrapment efficiency is found with the HLB value of 
8.6. 
2. Nature of Encapsulated Drug: The charge and the 
rigidity of the niosomal bilayer are greatly influenced by 
physical chemical properties of the encapsulated drug. 
Entrapment of drug occurs by interacting with the 
surfactant head groups leading to the increasing charge 
and creates mutual repulsion of the surfactant bilayer 
and thus increases the vesicle size. The HLB of drug 
influences the degree of entrapment. 
3. Hydration Temperature: The size and shape of the 
niosome are affected by the temperature of hydration. 
Hydration temperature should be above the gel, liquid 
phase transition temperature. Change in temperature 
affects the assembly of surfactants into vesicles and 
vesicle shape modification. Hydration time and volume 
of hydration medium also accounts for the modification. 
Improper selection of the hydration temperature, time 
and hydration medium volume produces fragile 
niosomes / drug leakage problems may arise. 
4. Cholesterol Content: Incorporation of cholesterol 
increases the entrapment efficiency and hydro-dynamic 
diameter of niosomes. Cholesterol acts in two ways:  
 Increases the chain order of liquid state bilayers.  
 Decreases the chain order of gel state bilayers.  
An increase in the cholesterol concentration causes an 
increase in the rigidity of the bilayers and decrease in the 
release rate of encapsulated material. 
Drug 
Nature of 
surfactant 
Hydration 
temperature 
Nature of 
encapsulated 
drug 
Charge 
Cholesterol 
content 
Resistance 
to osmotic 
stress 
Factors 
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 5. Charge: Presences of charge leads to an increase in 
inter lamellar distance between successive bilayers in 
multi lamellar vesicle structure and greater overall 
entrapped volume. 
 6. Resistance to Osmotic Stress: Addition of 
hypertonic solution causes reduction in vesicle diameter. 
In hypotonic solution, inhibition of eluting fluid from 
vesicles results in the slow release initially followed by 
the faster release due to the mechanical loosening of 
vesicle structure under osmotic stress. 
SEPARATION OF UNENTRAPPED DRUG 26,27,28  
The removal of unentrapped solute from the vesicles can 
be accomplished by various techniques, which include: - 
1) Dialysis: The aqueous niosomal dispersion is 
dialyzed in dialysis tubing against phosphate buffer or 
normal saline or glucose solution. 
2) Gel Filtration: The unentrapped drug is removed by 
gel filtration of niosomal dispersion through a Sephadex-
G-50 column and elution with phosphate buffered saline 
or normal saline. 
3) Centrifugation: The niosomal suspension is 
centrifuged and the supernatant is separated. The pellet 
is washed and then resuspended to obtain a niosomal 
suspension free from unentrapped drug. 
CHARACTERIZATION OF NIOSOMES 
29-35
 
1. Bilayer Rigidity and Homogeneity: The 
biodistribution and biodegradation of niosomes are 
influenced by rigidity of the bilayer. In homogeneity can 
occur both within niosome structures and between 
niosomes in dispersion and could be identified via. p-
NMR, Differential scanning calorimetry (DSC) and 
Fourier transform-infra red spectroscopy (FT-IR) 
techniques. 
2. Size and Shape: Various methods is used for the 
determination of mean diameter like as laser light 
scattering method besides it also determines by electron 
microscopy, molecular sieve chromatography, photon 
correlation microscopy, optical microscopy. 
3. Stability Study: Niosomal formulations are subject to 
stability studies by storing at 4°C, 25°C and 37°C in 
thermostatic oven for the period of three months. After 
one month, drug content of all the formulations are 
checked by entrapping efficiency parameter. 
4. In-vitro Release: In-vitro release rate study carried 
out by the use of  
1. Dialysis Tubing, 
2. Reverse dialysis and  
3. Franz diffusion cell.  
a. Dialysis Tubing: A dialysis sac is washed with 
distilled water. The prepared vesicle suspension is 
pipetted into a bag made up of the tubing dialysis and 
after that the bag is sealed. Then the bag containing the 
vesicles is placed in 200 ml of buffer solution in a 250 
ml beaker with constant shaking at 25°C. At various 
time intervals, the buffer is an analysis of the drug 
content of an appropriate assay method.  
b. Reverse Dialysis: A number of small dialysis as 
containing 1ml of dissolution medium is placed in 
proniosomes. The proniosomes are then displaced into 
the dissolution medium. The direct dilution of the 
proniosomes is possible with this method and the rapid 
release cannot be quantified by using this method. 
c. Franz Diffusion Cell: The in vitro diffusion studies 
can be performed by using Franz diffusion cell. 
Proniosomes is placed in the donor chamber of a Franz 
diffusion cell fitted with cellophane membrane. The 
proniosomes is then dialyzed against a suitable 
dissolution medium at room temperature; the samples 
are withdrawn from the medium at suitable intervals and 
analyze for drug content using suitable method such as 
U.V spectroscopy, HPLC, etc. the maintenance of sink 
condition is essential. 
5. Scanning Electron Microscopy: The niosomes were 
observed under a scanning electron microscope (SEM) 
(JSM 6100 JEOL, Tokyo, Japan). They were mounted 
directly onto the SEM sample stub using double sided 
sticking tape and coated with gold film of thickness of 
200 nm under reduced pressure of 0.001 mmHg. 
Photographs were taken at suitable magnification. 
6. Vesicle Charge: The vesicle surface charge can play 
an important role in the behavior of niosomes in vivo 
and in vitro. Charged niosomes are more stable against 
aggregation and fusion then unchanged vesicles. In order 
to obtain an estimate of the surface potential, the zeta 
potential of individual niosomes can be measured by 
microelectrophoresis. An alternative approach is the use 
of pH-sensitive fluorophores. More recently, dynamic 
light scattering have been used to measure the zeta 
potential of niosomes. 
7. Niosomal Drug Loading and Encapsulation 
Efficiency : To determine drug loading and 
encapsulation efficiency, the niosomal aqueous 
suspension was ultracentrifuged, supernatant was 
removed and sediment was washed twice with distilled 
water in order to remove the adsorb drug. 
 The niosomal recovery can be calculated as: 
           
                            
                                 
     
 
 The entrapment efficiency (EE) was then calculated 
using formula: 
                      
                          
              
     
 The drug loading was calculated as: 
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NATURE OF DRUG AND ITS EFFECT ON STABILITY 
Table 4: Nature of drug and its effect on stability 
Nature of the Drug Leakage from the Vesicles Stability 
Hydrophobic drug Decreases Increases 
Hydrophobic drug Increases Decreases 
Amphiphilic drug Decreases - 
Macromolecules Decreases Increases 
 
APPLICATIONS OF NIOSOMES 
36-45 
The application of niosomal technology is widely varied 
and can be used to treat a number of diseases. 
1. Niosomes as Drug Carriers - Niosomes have also 
been used as carriers for iobitridol, a diagnostic agent 
used for X-ray imaging. 
2. Targeting of Bioactive Agents 
a. To Reticulo-Endothelial System (RES) - The cells 
of the RES preferentially take up the vesicles. The 
uptake of niosomes by the cells is also by circulating 
serum factors known as opsonins, which mark them for 
clearance. Such localized drug accumulation has, 
however, been exploited in the treatment of animal 
tumors known to metastasize to the liver and spleen and 
in parasitic infestation of the liver. 
b. To Organs, Other than RES - Carrier system can be 
directed to specific sites in the body by the use of 
antibodies . Immunoglobulins seem to bind quite readily 
to the lipid surface, thus offering a convenient means for 
targeting of drug carrier. Many cells possess the intrinsic 
ability to recognize and bind particular carbohydrate 
determinants and this can be exploited to the direct 
carriers system to particular cells. 
3. Anti-neoplastic Treatment - Most antineoplastic 
drugs cause severe side effects. Niosomes can alter the 
metabolism prolong the circulation and half life of the 
drug, decreasing the side effects of the drugs. Niosomes 
decrease the rate of proliferation of tumor and higher 
plasma levels by slower elimination. 
4. Leishmaniasis - Leishmaniasis is a disease in which 
a parasite of the genus Leishmania invades the cells of 
the liver and spleen. Niosomes use in tests, conduct and 
shows that it was possible to administer higher levels of 
the drug without the triggering of the side effects, allows 
greater efficacy in the treatment. 
5. Delivery of Peptide Drugs - Use of niosomes to 
successfully protect the peptides from gastrointestinal 
peptide breakdown is being investigated. In an in-vitro 
study conducts by oral delivery of a vasopressin entrap 
derivative in niosomes shows that entrapment of the 
drug increases the stability of the peptide. 
6. Use in Studying Immune Response - Due to their 
immune system selection, low toxicity, greater stability 
niosomes are used to study the nature of the immune 
response provoke by antigens. Non-ionic surfactant 
vesicles have clearly demonstrated their ability to 
function as adjuvants as parenteral administration with a 
number of different antigens and peptides. 
7. Cosmetics - The first report of non-ionic surfactant 
vesicles came from the cosmetic applications devised by 
L’Oreal. Niosomes develop and patent by L’Oréal in the 
1970s and 80s. The first product ‘Niosome’ introduce in 
1987 by Lancôme. Niosome advantage in cosmetic and 
skin care an application include their ability to increase 
the stability of entrapped drugs and also improves 
bioavailability of poorly absorb ingredients and 
enhances skin penetration. 
8. Other Applications- 
a) Sustained Release- Sustained release action of 
niosomes can be applied to drugs having a low 
therapeutic index and low water solubility then they 
maintains in the circulation via niosomal encapsulation. 
b) Localized Drug Action- Approach of nisomal drug 
delivery is to achieve local drug action, since their size 
and low penetrability through the epithelium and 
connective tissue keeps the drug localized at the site of 
administration. 
c) Niosome Formulation As A Brain Targeted 
Delivery System For The Vasoactive Intestinal 
Peptide (VIP)- Radio labelled (I125) VIP-load glucose 
bearing niosomes is injected intravenously to mice. 
Encapsulate VIP within glucose bearing niosomes 
exhibits higher VIP brain uptake as compared to control. 
d) Niosomes As Carriers For Hemoglobin - Niosomes 
can be used as a carrier for hemoglobin. Niosomal 
suspension shows a visible spectrum super-imposable to 
that of free hemoglobin. Vesicles are permeable to 
oxygen and hemoglobin dissociation curve can be 
modified similarly to non-encapsulate hemoglobin. 
ROUTE OF APPLICATION OF NIOSOMAL 
DRUG 
Table 5: Drugs used in Niosomal Delivery 
Route of 
Administration 
Examples of Drug 
Nasal Route Sumatriptan 
Transdermal Route Piroxicam, Nimesulide, Estradiol 
Intravenous Route Doxorubicin, Insulin, Rifampicin 
Ocular Route Cyclopentol 
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MARKETED FORMULATIONS OF NIOSOMES 
Table 6: Marketed Formulations of Niosomes 
S.No. Brand Name of the Product 
1. Lancome- Foundation and complexation Flash Retouch Brush on Concealer 
2. Britney Spears – Curious Curious Coffret: Edp Spray 100ml +Dualended Parfum & Pink 
Lipgloss + Body soufflé 100 ml 
3. Loris Azzaro – Chrome Chrome Eau De Toilette Spray 200 ml 
4. Orlane – Lipcolor and Lipstick Lip Gloss 
 
PATENT CITATIONS  
Table 7: Patent Citations 
Publication number Priority date Publication 
date 
Assignee Title 
US4873088A 1983-09-06 1989-10-10 Liposome Technology, 
Inc. 
Liposome drug delivery 
method and composition 
US4891208A * 1985-04-10 1990-01-02 The Liposome 
Company, Inc. 
Steroidal liposomes 
 
US5741515A * 1994-10-20 1998-04-21 Bayer Aktiengesellschaft Ketoprofen liposomes 
US6403056B1 * 1997-03-21 2002-06-11 Imarx Therapeutics, Inc Method for delivering 
bioactive agents using 
cochleates 
US6428811B1 * 1998-03-11 2002-08-06 Wm. Marsh Rice 
University 
Temperature-sensitive 
polymer/nanoshell composites 
for photothermally modulated 
drug delivery 
US20020143385A1 * 2000-03-13 2002-10-03 Jun Yang Stent having cover with drug 
delivery capability 
 
CONCLUSION 
Niosomes have been studied as an alternative to 
liposomes. Some advantages over liposomes, such as 
their relatively higher chemical stability, improved 
purity and relatively lower cost in comparison with 
liposomes. Non-ionic surfactant vesicles alter the 
plasma clearance kinetics, tissue distribution, 
metabolism and cellular interaction of the drug. 
FUTURE PROSPECTS 
Niosomes represent a promising drug delivery molecule. 
There is a lot of scope to encapsulate toxic anti-cancer 
drugs, anti-infective drugs, anti-AIDS drugs, anti-
inflammatory drugs, anti-viral drugs, etc. in niosomes 
and to use them as promising drug carriers to achieve 
better bioavailability and targeting properties and for 
reducing the toxicity and side-effects of the drugs. The 
ionic drug carriers are relatively toxic and unsuitable 
whereas niosomal carriers are safer. Handling and 
storage of niosomes require no special conditions. 
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